Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a pipeline of gene control medicines. Co.'s primary product candidates are: SY-1425, a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine, a hypomethylating agent frequently used to treat acute myeloid leukemia; and SY-5609, a selective oral inhibitor of cyclin-dependent kinase 7, that is being evaluated in the dose escalation portion of a clinical trial in patients with select advanced solid tumors. The SYRS stock yearly return is shown above.
The yearly return on the SYRS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SYRS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|